Using clinical and transcriptional data from breast cancer patients obtained from the TCGA Research Network, we have performed bioinformatical analyses comparing disease onset and progression in either ErbB2-positive or ErbB2 and nucleolin-positive breast cancer patients. Here, ERBB2 is linked to breast cancer.